Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: is it time to give the emperor a statin robe?

Nonalcoholic fatty liver disease (NAFLD) is increasingly being recognized as a major health epidemic. It is the most common chronic liver disease worldwide with a prevalence of 25% in the general population [1]. Type 2 diabetes (T2D) is a major risk factor for the development of NAFLD being prevalent in over 55% of those with T2D globally [2]. Cardiovascular (CV) disease (CVD) and cirrhosis/fibrosis are major causes of morbidity and mortality in NAFLD. Those with nonalcoholic steatohepatitis (NASH) are among those at the highest risk of CVD and mortality, with the presence of fibrosis being a key histologic prognostic factor [3,4].
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research